Atopic Dermatitis- Market will grow with novel therapies

DELHI, India - Oct. 6, 2017 - PRLog -- About


Atopic dermatitis (AD) is a chronic inflammatory skin disease and is characterized by widespread skin lesions, which manifest as red, itchy, swollen, cracked, weeping lesions with crusting/scaling, intractable pruritus (most common and persistent disease that is prevalent) and enhanced susceptibility to bacterial and viral skin infections. Atopic Dermatitis is also classified as Controlled Atopic Dermatitis and Uncontrolled Atopic Dermatitis on the basis of the disease controlled by using therapies.

Prevalence

The prevalence of uncontrolled Atopic Dermatitis is higher in adults as compared to children. In 2016 the total number of prevalent population of AD was estimated to be around 40 million and that of Pruritus in AD was estimated as 20.5 million in 7MM. The prevalent population of Uncontrolled AD in the U.S. was found to be approximately 7 million in 2016.United States accounts for the maximum number of AD cases followed by Europe and Japan. Japan has the least number of prevalent cases. DelveInsight estimates that the prevalent population of AD will significantly increase at a CAGR of 1.1% for the period 2015-2025 in 7 MM's.

Market Scenario

According to the latest report of DelveInsight, "Atopic Dermatitis – Market Insight, Epidemiology & Market Forecast, 2025", In 2016 the market size of AD was estimated to be around USD 2.2 billion in 7MM. Estimated market size of Pruritus in Atopic Dermatitis was estimated to be USD 1.8 billion in 2016 in 7MM. As per the estimates, a higher growth has been seen in the AD market during the period of 2015-2025 due to the expected launch of the new therapies. The market is estimated to grow at a CAGR of 14.52%.

Treatment Options

The market is dominated by the use of corticosteroids, immunosuppressants and calcineurin inhibitors for the treatment of Atopic Dermatitis. Various approved drugs are also available such as Elidel, Protopic, Desonate and pimecrolimus. Market has seen a positive growth after the approval of Eucrisa (Pfizer) and Dupilumab (Regeneron Pharmaceuticals/Sanofi) in 2016 and 2017 respectively due to their novel mechanism of action.

Upcoming therapies

The launch of the upcoming therapies in 2022 Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), 2021 RVT-501 (Roivant Sciences) and OPA-15406 (Otsuka Pharmaceutical) are expected to create a positive impact on the market size of Pruritus in Atopic Dermatitis.

Market Drivers and Market Barriers

Increasing prevalence, emerging drugs, growing government and pharmaceutical company's initiatives, and advancement in treatment are the market drivers for Atopic Dermatitis. On the other hand, lack of awareness, no approved drug, challenges in performing clinical trials, and use of low efficacy drugs are some of the market barriers.

The latest report has covered all the details related to the Atopic Dermatitis including the market share distribution in 2016 as well as in 2025. Complete epidemiological report with country-specific prevalent population data. Complete treatment algorithm with marketed drug profiling as well as emerging therapy details. It provides clear idea about the unmet needs and all the possible market drivers and barriers.

Companies Mentioned:

·         Galderma Pharma

·         LEO Pharma

·         Vanda Pharmaceuticals

·         Novartis

·         Nippon Shinyaku

·         Menlo Therapeutics

·         DS Biopharma

·         Tioga Pharmaceuticals

·         GlaxoSmithKline

·         Roche

·         Sienna Biopharmaceutical

·         And many others……………

  For report store please visit: https://www.delveinsight.com/report-store.php